Arvinas, Inc. (NasdaqGS: ARVN)
Health Care · Pharmaceuticals · US
$7.51
+0.81% today · -23.0% 1Y
Arvinas, Inc. (NasdaqGS: ARVN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $491.05M and employs 246 people.
Over the last twelve months the share price has lost 23.0%, trading between 6.97 and 14.51.
Tweenvest scores Arvinas, Inc. across four factors: quality 43/100, value 43/100, growth 100/100. Its strongest factor is growth.
ARVN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $491.05M
- Revenue (TTM)
- $316.70M
- P/E
- 56.18
- EPS
- 0.13
- Dividend yield
- —
- Beta (5Y)
- 1.81
- 52-week high
- $14.51
- 52-week low
- $6.97
- Avg volume (3M)
- —
- Shares outstanding
- 65.39M
- Employees
- 246
- Next earnings
- —
About Arvinas, Inc.
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
- ISIN
- US04335A1051
- Founded
- 2013
- Listed since
- Sep 27, 2018
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Tibet AIM Pharm. Inc.SZSE: 002826 | $498.43M | CN¥17.59 | -0.51% |
| Contineum Therapeutics, Inc.NasdaqGS: CTNM | $495.85M | $13.18 | +3.53% |
| Zhejiang Haisen Pharmaceutical Co., Ltd.SZSE: 001367 | $493.30M | CN¥22.01 | +2.37% |
| Hinova Pharmaceuticals Inc.SHSE: 688302 | $492.14M | CN¥33.34 | +1.37% |
| Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim SirketiIBSE: GENIL | $485.30M | TL5.30 | -27.89% |
| PKU HealthCare Corp.,Ltd.SZSE: 000788 | $485.12M | CN¥5.46 | +1.49% |
| Daewoong Co., Ltd.KOSE: A003090 | $478.81M | ₩15,340.00 | -3.46% |
| iX Biopharma Ltd.Catalist: 42C | $478.80M | S$0.56 | +2.75% |
Figures last refreshed Oct 4, 2026.